AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) is a proprietary platform available exclusively through partnerships with Alloy. Sudhir Agrawal, D.Phil, inventor of the underlying IP for the ...
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target ...
Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...
DALLAS, TX and MARTINSRIED, GERMANY / ACCESSWIRE / March 20, 2024 / Celanese Corporation (NYSE:CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a ...
Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...
The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities. A research team from ...
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a ...
As people age, it becomes harder to know who is on track for healthy years ahead and who may be at higher risk for serious decline. A new study suggests that part of the answer may already be ...
A drug that halts an AIDS-related eye infection could be the first antisense therapy to reach the market. However, whether the drug can truly be called "antisense" depends on some specifics--such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results